Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMD-477 in Type 2 Diabetes Mellitus
NCT05093517Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- Nov 2021
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing REMD-477 with Placebo (2 arms). Primary endpoints: Glycated Hemoglobin at 13 weeks, Fasting Plasma Glucose at 13 weeks and 5 more. Started Nov 2021; status: completed.
02
Drugs
volagidemab
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05093517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093517.